By contrast, two single-group phase 1/2 studies showed that the combination of fulvestrant plus capivasertib resulted in objective response rates of 20–36% for advanced ER-positive, HER2-negative breast cancer that carried the activating AKT1 E17K mutation, even after previous treatment with fulvestrant. Here, ERBB2 is linked to breast cancer.